Once-monthly efimosfermin for non-cirrhotic MASH

Key Points

• Efimosfermin demonstrates significant improvements in biomarkers for non-cirrhotic MASH, indicating potential therapeutic success.
• A 12-week treatment period showed substantial changes in liver function markers, highlighting its effectiveness.
• This analysis assesses patient outcomes using efimosfermin, combining clinical evaluations and laboratory tests as methods.
• These findings suggest that efimosfermin may provide a new treatment avenue for non-cirrhotic MASH, warranting further research.